Do AMH Levels Truly Predict Ovarian Reserve in Women Over 30?
BACKGROUND AND PURPOSE:
Antimüllerian hormone (AMH) is used clinically during fertility treatments prior to ovarian stimulation
Low levels (<1 ng/mL) is a predictor of poor prognosis for live birth and can guide medical management
Biomarkers such as AMH are commercially available to help women, without history of infertility, to predict whether they are at risk for early (<45 years of age) or premature (<40 years) loss of ovarian function
Steiner et al. (JAMA, 2017) sought to determine whether such biomarkers (AMH/FSH/inhibin B) are associated with reproductive potential in noninfertile women of older reproductive age
Prospective time-to-pregnancy cohort study (2008-2016)
981 women aged 30 to 44 years with no history of infertility who had been trying to conceive for 3 months or less
Cumulative probability of conception by 6 and 12 cycles
Relative fecundability (probability of conception during a menstrual cycle)
Conception was defined as a positive pregnancy test result
Results adjusted for age, body mass index, race, current smoking status, and recent hormonal contraceptive use
750 women were included
When comparing women with low AMH values (<0.7 ng/mL) to those with normal values, there was no difference in predicted probability of conceiving
6 cycles: 65% vs 62%
12 cycles: 84% vs 75%
When comparing women with high serum FSH values (>10 mIU/mL) to those with normal values, there was no difference in predicted probability of conceiving
6 cycles: 63% vs 62%
12 cycles: 82% vs 75%
When comparing women with high urinary FSH values (>11.5 mIU/mg creatinine) to those with normal values, there was no difference in predicted probability of conceiving
6 cycles: 61% vs 62%
12 cycles: 70% vs 76%
Inhibin B levels were not associated with the probability of conceiving
The use of urinary/blood FSH or AMH tests as biomarkers in noninfertile women to predict natural fertility is not supported based on the evidence presented in this study
OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Jointly provided by
NOT ENOUGH CME HOURS
It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan